BCX Bioceltix S.A.

GPW · PL · Healthcare · Biotechnology · bioceltix.com

71.80PLN-2.31%Mkt Cap: 100.60M $P/E: —Today

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BC…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap100.60M USD

Enterprise Value87.64M USD

Revenue (TTM)—

Gross Profit-517.47K USD

Net Income (TTM)-3.84M USD

Revenue/Share—

Last Price71.80 PLN

Fiscal Year EndDec 2025

MR QuarterMar 2026

Employees46

CountryPL

SectorHealthcare

IndustryBiotechnology

ISINPLBCLTX00019

Valuation

P/E (Trailing)—

P/E (Forward)-38.68

PEG—

EV/EBITDA-21.03

EV/Revenue—

P/S—

P/B6.02

EPS (TTM)-3.47

EPS (Forward)—

52W Range

70.005% of range104.60

52W High104.60 PLN

52W Low70.00 PLN

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-20.69%

ROA-20.04%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-3.03M USD

CapEx (TTM)498.97K USD

FCF Margin—

FCF Yield-3.79%

Net Debt-15.34M USD

Net Debt/EBITDA3.68

Balance Sheet

Debt/Equity0.00

Current Ratio22.56

Quick Ratio22.49

Book Value/Sh12.22 PLN

Cash/Share10.99 PLN

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 PLN

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)133.00 PLN

Upside (mean)+85.2%

Target Range133.00 PLN – 133.00 PLN

# Analysts1

Ownership

Shares Out.5.53M

Float4.44M

Insiders15.12%

Institutions28.83%

Technical

SMA 5079.90 (-10.1%)

SMA 20082.67 (-13.2%)

Beta0.91

S&P 52W Chg14.58%

Avg Vol (30d)3.20K

Avg Vol (10d)2.58K

Technical Indicators

RSI (14)31.2

MACD-1.5301

MACD Signal-1.7551

MACD Hist.+0.2250

BB Upper77.82 PLN

BB Middle75.78 PLN

BB Lower73.73 PLN

BB Width5.41%

ATR (14)1.462 PLN

Vol Ratio (20d)2.02x